Novo Nordisk A/S (NYSE:NVO) Lowered to Strong Sell Rating by Zacks Research

Novo Nordisk A/S (NYSE:NVO) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Monday,Zacks.com reports.

Other equities analysts have also issued reports about the company. Morgan Stanley reiterated an “underweight” rating and issued a $42.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a report on Thursday, January 22nd. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $56.07.

Novo Nordisk A/S Trading Down 0.7%

NYSE:NVO opened at $49.04 on Monday. The company’s 50 day moving average is $53.66 and its 200-day moving average is $53.42. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $93.80. The firm has a market cap of $218.96 billion, a price-to-earnings ratio of 14.13 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Institutional Trading of Novo Nordisk A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. True Wealth Design LLC boosted its holdings in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares in the last quarter. Guerra Advisors Inc bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $25,000. Godfrey Financial Associates Inc. acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at $25,000. WealthCollab LLC grew its position in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the period. Finally, American National Bank & Trust acquired a new position in Novo Nordisk A/S during the fourth quarter worth $28,000. Institutional investors own 11.54% of the company’s stock.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Hims & Hers pulled its compounded semaglutide offering after FDA scrutiny and Novo’s legal threats, removing an immediate self-pay price competitor and giving short-term relief to Novo’s pricing outlook. Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide
• Positive Sentiment: Novo launched a share repurchase programme (part of a DKK 15bn plan) which supports the stock via buybacks and signals capital-allocation flexibility. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: Novo’s patent lawsuit against Hims & Hers escalates enforcement of its Wegovy patents — this defends pricing and market share if courts or settlements curb copycat offerings. Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
• Neutral Sentiment: Insiders and executives reported transactions in company shares (regulatory disclosure) — note for governance/positioning but not necessarily directional. Trading in Novo Nordisk shares by board members, executives and associated persons
• Neutral Sentiment: Market interest and coverage remain high (trending stories and analyst notes), so volatility is likely to continue while investors digest guidance and legal outcomes. Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
• Negative Sentiment: The FDA told Novo that a TV ad for its Wegovy pill included “false or misleading” claims, raising regulatory risk and potential limits on promotional activities. FDA says Novo’s obesity pill TV Ad is false or misleading
• Negative Sentiment: Weak 2026 guidance and a pronounced slowdown in EPS growth prompted a large re-rating and technical/downgrade commentary suggesting deeper downside risk; some technical analysts flag support much lower than current levels. Novo Nordisk: How Low Is Too Low? (Downgrade, Technical Analysis)
• Negative Sentiment: Analysts (e.g., BofA) have cut EPS forecasts and trimmed price targets after the weak outlook, which increases downside pressure until guidance visibility improves. Where is Novo Nordisk A/S (NVO) Headed?

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.